bicalutamide has been researched along with vorinostat in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Azizi, B; Doyle, DF; Gryder, BE; Johnson, KA; Oyelere, AK; Patil, V; Raftery, ED; Rice, M; Rood, MK; Yao, LP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bianco-Miotto, T; Butler, LM; Evdokiou, A; Marks, PA; Marrocco, DL; Richon, VM; Rifkind, RA; Scher, HI; Tilley, WD | 1 |
| Butler, LM; Carter, SL; Centenera, MM; Selth, LA; Tilley, WD | 1 |
1 review(s) available for bicalutamide and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for bicalutamide and vorinostat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Drug Discovery; Estrogen Receptor Modulators; Histone Deacetylase Inhibitors; Humans; Molecular Docking Simulation; Receptors, Estrogen; Structure-Activity Relationship | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Topics: Androgen Receptor Antagonists; Anilides; Anticarcinogenic Agents; Cell Cycle; Cell Death; Cell Proliferation; Cell Survival; Culture Media; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Male; Neoplasm Proteins; Nitriles; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Steroids; Tosyl Compounds; Tumor Cells, Cultured; Vorinostat | 2007 |
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Profiling; Humans; Hydroxamic Acids; I-kappa B Proteins; Male; NF-KappaB Inhibitor alpha; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Vorinostat | 2016 |